Drugs moving into the clinic: 29
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| MerLion Pharmaceuticals | Finafloxacin | Oncology & Anti-infectives & Vaccines - Helicobacter pylori antibiotic (linked to gastric ulceration and gastric cancer) | pH activated antibiotic |
| Affibody | Her-2 Affibody | Oncology - breast cancer | Antibody alternative that is tagged by a radionuclide and so can be used as targeted therapy or diagnostic - the latter being the case with this trial |
| Biotie & Roche | undisclosed | Inflammation | Human Vascular Adhesion Protein-1 (VAP-1) monoclonal antibody |
| Pharmacopeia & Schering-Plough | PS948115 | respiratory disease | undisclosed |
| VaxInnate Corporation | M2e vaccine | Anti-infectives & Vaccines - influenza | Targets the M2 ectodomain (M2e) portion of the flu virus, which is inherent regardless of virus strain |
| University of Alberta | dichloroacetate | Oncology - glioblastoma | Dichloroacetate (DCA) retores mitochondrial function, thus restoring apoptosis. Phase II trial approved by Health Canada, but no Phase I ever been done. Develpoed privately as moelcule can't be patented |
